Caricamento...
Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
SGLT-2 inhibitors have recently emerged as an important class of oral drugs for treatment of type 2 diabetes mellitus, especially in patients with cardiovascular or renal impairment, recommended in all recent treatment guidelines. They have additional advantages of weight and blood pressure reductio...
Salvato in:
| Pubblicato in: | Diabetol Int |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Singapore
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8172658/ https://ncbi.nlm.nih.gov/pubmed/34150432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13340-020-00472-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|